47例原发性胃肠道非霍奇金淋巴瘤临床及预后分析  

Clinical and prognosis analysis of 47 cases with primary gastrointestinal non-Hodgkin's lymphoma

作　　者：樊光华[1] 刘展[2] 

机构地区：[1]江西省肿瘤医院化疗中心,南昌330029 [2]湖南省人民医院消化科,长沙410007

出　　处：《江西医药》2005年第11期703-705,共3页Jiangxi Medical Journal

摘　　要：目的探讨原发性胃肠道非霍奇金淋巴瘤(PGI-NHL)的预后相关因素与临床疗效之间的关系。方法回顾性分析经病理检查确诊的47例PGI-NHL患者的临床资料、病理类型、治疗方式;按上述变量分组,分别统计其3年及5年生存率,探讨各变量与生存率之间的关系。结果(1)本研究所有病例均随访5年以上,3、5年总生存率分别为55.3%(26/47)、42.6%(20/47);(2)3年和5年生存率:Ⅰ、Ⅱ期患者为65.7%(23/35)、51.4%(18/35),Ⅲ、Ⅳ期患者为25.0%(3/12)、16.7%(2/12)(P<0.01)。肿块直径≤10cm者为80.0%(20/25)、64.0%(16/25),肿块直径>10cm者为27.3%(6/22)、18.2%(4/22),(P<0.01)。低度恶性者为82.4%(14/17)、64.7%(11/17),中/高度恶性者为40.0%(12/30)、30.0%(9/30),(P<0.05)。B细胞型PGI-NHL为63.2%(24/38)、52.6%(20/38),而T细胞型PGI-NHL为22.2%(2/9)、0.0%(0/9),(P<0.01)。血清乳酸脱氢酶(Serumlactatedehydrogenase,LDH)≤500IU/L者为70.0%(21/30)、56.7%(17/30),LDH>500IU/L者为29.4%(5/17)、17.6%(3/17),(P<0.01)。手术+化疗组为71.0%(22/31)、58.1%(18/31),单纯手术组为25.0%(4/16)、12.5%(2/16),(P<0.01)。结论临床分期、肿瘤大小、病理免疫表型、血清乳酸脱氢酶高低、治疗措施为影响PGI-NHL预后的重要因素。Objective To evaluate the factors related to prognosis of primary gastrointestinal non-Hodgkin＇s lymphoma （PGI-NHL）,and to analyze the factors of these influence on treatment outcome.Methods Retrospectively analysed the clinical features,pathological type,therapeutic t,ethods in 47 patients with PGI-NHL;The patients were divided into different groups according to these variables, and caculated the corresponding 3-and 5-year survival rate,and then,evaluated their correlation.Results （1）All the patients were followed up for more than 5 years,The overall survival rates at 3- and 5-year were 55,3% （26/47）and 42.6%（20/47）,respectively.（2） 3- and 5-year survival rate：In palienls of slageⅠ, Ⅱ ,the 3- and 5-year survival tales were 65.7%（23/35）and 51.4%（18/35） ;In slage Ⅲ,Ⅳ,were 25.0%（3/12） and 16,7% （2/12）（P〈0,01 ）, In the patieuts with lesions 10cm or less, the 3- and 5-year survival rates were 80.0%（20/25） and 64,0%（16/25）;those with lesions more than 10cm were 27.3%（6/22） and 18.2%（4/22）,respectively （P〈0.01）, Low-grade PG1-NHL were 82.4%（14/17） and 64.7%（11/17） ;Those moderate-grade and hlgh-grade ones were 40.0%（12/30） and 30.0%（9/30）, （P〈0.05）,B-cell type PG1-NHL were 63.2%（24/38） and 52.6%（20/38）; Those T-cell PGI-NHL were 22.2%（2/9） and 0.0%（0/9）, （P〈0.01）, The patients with serum lactate dehydrogenase （LDH） 2001U/L or less were 70.0%（21/30） and 56,7%（ 17/ 30）; those with more than 5001U/L were 29.4%（5117） and 17.6%（3/17）, （P〈0.01）,In the cases treated with surgery plus chemotherapy, the 3- and 5-year survival rates were 71.0%（22/31 ） and 58.1%（ 18/31 ）;In the ones treated with surgery alone were 25.0%（4/ 16） and 12.5%（2/16）, （P〈0.01）.Conclusion Clinical stage,tumor size,histological immunophenotype,LDH level,therapeutic measure were prognostic risk facoors for PGI-NHL.

关 键 词：淋巴瘤 非霍奇金 胃肠道 临床研究 预后 

分 类 号：R735[医药卫生—肿瘤]